300
Participants
Start Date
May 31, 2007
Primary Completion Date
November 30, 2009
Ad5FGF-4
Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
Placebo
Control group
Lenox Hill Heart & Vascular Institute, New York
Heritage Cardiology Associates, Camp Hill
Geisinger Clinic, Danville
Cardiovascular Research Institute, Washington D.C.
Duke University Medical Center, Durham
St Joseph's Research Institute, Atlanta
University of Florida, Gainesville
Florida Hospital, Orlando
University of Alabama, Birmingham
Meharry Medical College, Nashville
The Stern Cardiovascular Center, Germantown
Cardiovascular Associates, Louisville
North Ohio Heart Center, Elyria
The Lindner Clinical Trial Center, Cincinnati
The Care Group, Indianapolis
Northern Indiana Research Alliance, Fort Wayne
William Beaumont Hospital, Royal Oak
University of Michigan Medical Center, Ann Arbor
Care Foundation, Wausau
Minneapolis Heart Institute, Minneapolis
St. Mary's Duluth Clinic, Duluth
Midwest Heart Foundation, Lombard
Fox Valley Cardiovascular Consultants, Aurora
St. Anthony's Medical Center, St Louis
Mid America Heart Institute, Kansas City
Creighton University, Omaha
BryanLGH Heart Institute, Lincoln
Oklahoma Cardiovascular Associates, Oklahoma City
Baylor University Medical Center at Dallas, Dallas
Cardiovascular Associates of East Texas, Tyler
South Texas Cardiovascular Consultants, San Antonio
Aurora Denver Cardiology, Aurora
South Denver Cardiology, Littleton
St. Luke's Idaho Cardiology Associates, Boise
Banner Heart Hospital, Phoenix
Southwest Heart, Tucson
Cedars-Sinai Medical Center, Los Angeles
Access Clinical Trials, Beverly Hills
UCSD Medical Center, San Diego
Mission Internal Medical Group, Mission Viejo
Providence Heart & Vascular Institute, Portland
Swedish Medical Center, Seattle
Maine Medical Center, Portland
Massachusetts General Hospital, Boston
The Valley Hospital, Ridgewood
The Miriam Hospital, Providence
Fletcher Allen Health Care, Burlington
Lead Sponsor
Cardium Therapeutics
INDUSTRY